D. Rodriguez-abreu, A. Bordoni, and E. Zucca, Epidemiology of hematological malignancies, Annals of Oncology, vol.18, issue.Supplement 1, pp.3-8, 2007.
DOI : 10.1093/annonc/mdl443

URL : https://academic.oup.com/annonc/article-pdf/18/suppl_1/i3/6672797/mdl443.pdf

S. Alibhai, M. Leach, M. Minden, and J. Brandwein, Outcomes and quality of care in acute myeloid leukemia over 40 years, Cancer, vol.245, issue.(32), pp.2903-2911, 2009.
DOI : 10.1016/S0950-3536(11)80033-8

C. Stresemann and F. Lyko, Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine, International Journal of Cancer, vol.35, issue.1, pp.8-13, 2008.
DOI : 10.1128/MCB.4.10.2098

K. Lin, R. Momparler, and G. Rivard, High-performance Liquid Chromatographic Analysis of Chemical Stability of 5-aza-2???-Deoxycytidine, Journal of Pharmaceutical Sciences, vol.70, issue.11
DOI : 10.1002/jps.2600701112

A. European-medicines, Dacogen: summary of product characteristics Available from, 2017.

M. Nieto, P. Demolis, and E. Behanzin, The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use, The Oncologist, vol.21, issue.6, pp.692-700, 2016.
DOI : 10.1634/theoncologist.2015-0298

. Briot, Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion, Cancer Lett, vol.331, issue.1, pp.122-129, 2013.

Y. Cui, A. Naz, D. Thompson, and J. Irudayaraj, Decitabine Nanoconjugate Sensitizes Human Glioblastoma Cells to Temozolomide, Molecular Pharmaceutics, vol.12, issue.4, pp.1279-1288, 2015.
DOI : 10.1021/mp500815b

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689316/pdf

Y. Neupane, M. Sabir, N. Ahmad, M. Ali, and K. Kohli, gut permeation studies, Nanotechnology, vol.24, issue.41, pp.415102-415113, 2013.
DOI : 10.1088/0957-4484/24/41/415102

Y. Neupane, M. Srivastava, N. Ahmad, N. Kumar, A. Bhatnagar et al., Lipid based nanocarrier system for the potential oral delivery of decitabine: Formulation design, characterization, ex vivo, and in vivo assessment, International Journal of Pharmaceutics, vol.477, issue.1-2, pp.601-612, 2014.
DOI : 10.1016/j.ijpharm.2014.11.001

E. Roger, F. Lagarce, E. Garcion, and J. Benoit, Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery, Nanomedicine, vol.83, issue.2, pp.287-306, 2010.
DOI : 10.1152/physrev.00001.2003

B. Heurtault, P. Saulnier, B. Pech, J. Proust, and J. Benoit, A novel phase inversion-based process for the preparation of lipid nanocarriers, Pharmaceutical Research, vol.19, issue.6, pp.875-880, 2002.
DOI : 10.1023/A:1016121319668

N. Huynh, C. Passirani, P. Saulnier, and J. Benoit, Lipid nanocapsules: A new platform for nanomedicine, International Journal of Pharmaceutics, vol.379, issue.2, pp.201-209, 2009.
DOI : 10.1016/j.ijpharm.2009.04.026

E. Roger, F. Lagarce, and J. Benoit, Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration, European Journal of Pharmaceutics and Biopharmaceutics, vol.79, issue.1
DOI : 10.1016/j.ejpb.2011.01.021

B. Saliou, O. Thomas, and N. Lautram, Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide, European Journal of Pharmaceutical Sciences, vol.50, issue.2, pp.172-180, 2013.
DOI : 10.1016/j.ejps.2013.06.013

M. Eissa, R. El-moslemany, A. Ramadan, E. Amer, M. El-azzouni et al., Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study, PLOS ONE, vol.12, issue.2, p.141788, 2015.
DOI : 10.1371/journal.pone.0141788.t005

A. Laine, A. Clavreul, and A. Rousseau, Inhibition of ectopic glioma tumor growth by a potent ferrocenyl drug loaded into stealth lipid nanocapsules, Nanomedicine: Nanotechnology, Biology and Medicine, vol.10, issue.8, pp.1667-1677, 2014.
DOI : 10.1016/j.nano.2014.05.002

URL : https://hal.archives-ouvertes.fr/hal-01624361

A. Ramadan, F. Lagarce, and A. Tessier-marteau, Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study, Int J Nanomedicine, vol.6, pp.2941-2951, 2011.

K. Messaoudi, P. Saulnier, K. Boesen, J. Benoit, and F. Lagarce, Antiepidermal growth factor receptor siRNA carried by chitosantransacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide, Int J Nanomedicine, vol.9, pp.1479-1490, 2014.

M. Morille, T. Montier, and P. Legras, Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting, Biomaterials, vol.31, issue.2, pp.321-329, 2010.
DOI : 10.1016/j.biomaterials.2009.09.044

URL : https://hal.archives-ouvertes.fr/inserm-00491402

S. Vrignaud, A. N. Gayet, P. Benoit, J. Saulnier, and P. , Reverse micelle-loaded lipid nanocarriers: A novel drug delivery system for the sustained release of doxorubicin hydrochloride, European Journal of Pharmaceutics and Biopharmaceutics, vol.79, issue.1, pp.197-204, 2011.
DOI : 10.1016/j.ejpb.2011.02.015

S. Vrignaud, J. Hureaux, S. Wack, J. Benoit, and P. Saulnier, Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride, International Journal of Pharmaceutics, vol.436, issue.1-2, pp.194-200, 2012.
DOI : 10.1016/j.ijpharm.2012.06.026

S. Peltier, J. Oger, F. Lagarce, W. Couet, and J. Benoit, Enhanced Oral Paclitaxel Bioavailability After Administration of Paclitaxel-Loaded Lipid Nanocapsules, Pharmaceutical Research, vol.47, issue.6, pp.1243-1250, 2006.
DOI : 10.1111/j.1768-322X.1987.tb00571.x

L. Reed and H. Muench, A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12, American Journal of Epidemiology, vol.27, issue.3, pp.493-497, 1938.
DOI : 10.1093/oxfordjournals.aje.a118408

T. Qin, J. Jelinek, S. J. Shu, J. Issa, and J. , Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines, Blood, vol.113, issue.3, pp.659-667, 2009.
DOI : 10.1182/blood-2008-02-140038

Y. Neupane, M. Srivastava, N. Ahmad, K. Soni, and K. Kohli, Stability indicating RP-HPLC method for the estimation of decitabine in bulk drug and lipid based nanoparticles, Int J Pharm Sci Res, vol.7, pp.294-302, 2014.

W. Hua, T. Ierardi, M. Lesslie, B. Hoffman, and D. Mulvana, Development and validation of a HILIC???MS/MS method for quantification of decitabine in human plasma by using lithium adduct detection, Journal of Chromatography B, vol.969, pp.117-122, 2014.
DOI : 10.1016/j.jchromb.2014.08.012

S. David, P. Resnier, A. Guillot, B. Pitard, J. Benoit et al., siRNA LNCs ??? A novel platform of lipid nanocapsules for systemic siRNA administration, European Journal of Pharmaceutics and Biopharmaceutics, vol.81, issue.2, pp.448-452, 2012.
DOI : 10.1016/j.ejpb.2012.02.010

S. Li, R. Sun, and H. Wang, Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells, Journal of Controlled Release, vol.205, pp.7-14, 2015.
DOI : 10.1016/j.jconrel.2014.11.011

X. Su, Z. Wang, and L. Li, Lipid???Polymer Nanoparticles Encapsulating Doxorubicin and 2???-Deoxy-5-azacytidine Enhance the Sensitivity of Cancer Cells to Chemical Therapeutics, Molecular Pharmaceutics, vol.10, issue.5, pp.1901-1909, 2013.
DOI : 10.1021/mp300675c

A. Paillard, F. Hindre, C. Vignes-colombeix, J. Benoit, and E. Garcion, The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability, Biomaterials, vol.31, issue.29, pp.7542-7554, 2010.
DOI : 10.1016/j.biomaterials.2010.06.024

M. Howard, X. Lu, M. Jay, and T. Dziubla, Optimization of the lyophilization process for long-term stability of solid???lipid nanoparticles, Drug Development and Industrial Pharmacy, vol.38, issue.10, pp.1270-1279, 2012.
DOI : 10.1039/c39800000104

C. Dulieu and D. Bazile, Influence of Lipid Nanocapsules Composition on Their Aptness to Freeze-Drying, Pharmaceutical Research, vol.70, issue.2, pp.285-292, 2005.
DOI : 10.1007/s11095-004-1196-0

M. Karahoca and R. Momparler, Pharmacokinetic and pharmacodynamic analysis of 5-aza-2???-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy, Clinical Epigenetics, vol.5, issue.1, p.3, 2013.
DOI : 10.1002/cncr.11543

P. He, J. Zhou, and D. Yao, Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis, Oncotarget, vol.8, issue.25, pp.41498-41507, 2017.
DOI : 10.18632/oncotarget.17241

C. Arimany-nardi, E. Errasti-murugarren, and G. Minuesa, Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors, British Journal of Pharmacology, vol.321, issue.Pt 3, pp.3868-3880, 2014.
DOI : 10.1016/S0022-2836(02)00676-9

K. Ueda, M. Hosokawa, and S. Iwakawa, Cellular Uptake of Decitabine by Equilibrative Nucleoside Transporters in HCT116 Cells, Biological and Pharmaceutical Bulletin, vol.38, issue.8, pp.1113-1119, 2015.
DOI : 10.1248/bpb.b14-00622

P. Lansakara, B. Rodriguez, and Z. Cui, Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles, International Journal of Pharmaceutics, vol.429, issue.1-2, pp.123-134, 2012.
DOI : 10.1016/j.ijpharm.2012.03.014

D. Sullivan, . Jr, S. Gad, and M. Julien, A review of the nonclinical safety of Transcutol??, a highly purified form of diethylene glycol monoethyl ether (DEGEE) used as a pharmaceutical excipient, Food and Chemical Toxicology, vol.72, pp.40-50, 2014.
DOI : 10.1016/j.fct.2014.06.028

L. Roux, G. Moche, H. Nieto, A. Benoit, J. Nesslany et al., Cytotoxicity and genotoxicity of lipid nanocapsules, Toxicology in Vitro, vol.41, pp.189-199, 2017.
DOI : 10.1016/j.tiv.2017.03.007

C. Maupas, B. Moulari, A. Beduneau, A. Lamprecht, and Y. Pellequer, Surfactant dependent toxicity of lipid nanocapsules in HaCaT cells, International Journal of Pharmaceutics, vol.411, issue.1-2, pp.136-141, 2011.
DOI : 10.1016/j.ijpharm.2011.03.056

D. Liu, Recent advances in myelodysplasia: update from 2011 ASH annual meeting, Journal of Hematology & Oncology, vol.5, issue.Suppl 1, p.4, 2012.
DOI : 10.1182/blood-2011-09-377275

URL : https://doi.org/10.1186/1756-8722-5-s1-a4

E. Roger, F. Lagarce, E. Garcion, and J. Benoit, Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis, Journal of Controlled Release, vol.140, issue.2, pp.174-181, 2009.
DOI : 10.1016/j.jconrel.2009.08.010

D. Lavelle, K. Vaitkus, and Y. Ling, Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine, Blood, vol.119, issue.5, pp.1240-1247, 2012.
DOI : 10.1182/blood-2011-08-371690

J. Issa, G. Roboz, and D. Rizzieri, Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study, The Lancet Oncology, vol.16, issue.9, pp.1099-1110, 2015.
DOI : 10.1016/S1470-2045(15)00038-8

E. Roger, J. Gimel, C. Bensley, A. Klymchenko, and J. Benoit, Lipid nanocapsules maintain full integrity after crossing a human intestinal epithelium model, Journal of Controlled Release, vol.253, pp.11-18, 2017.
DOI : 10.1016/j.jconrel.2017.03.005